Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer

<p>Supplementary Table S2. Results of single-sample gene set enrichment analysis (ssGSEA) of transcriptomic profiles from HCC-1428 and HCC-1428/LTED cells.</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Nicole A. Traphagen (16677391) (author)
Altres autors:	Gary N. Schwartz (16005870) (author), Steven Tau (16677394) (author), Alyssa M. Roberts (16677397) (author), Amanda Jiang (15117790) (author), Sarah R. Hosford (16677400) (author), Jonathan D. Marotti (16005879) (author), Abigail E. Goen (16677403) (author), Bianca A. Romo (16677406) (author), Anneka L. Johnson (16677409) (author), Emily-Claire K. Duffy (16677412) (author), Eugene Demidenko (16005894) (author), Paul Heverly (16677415) (author), Yaron Mosesson (16677418) (author), Shannon M. Soucy (16005888) (author), Fred Kolling (16005891) (author), Todd W. Miller (16005897) (author)
Publicat:	2025
Matèries:	Cancer Therapeutic Research and Development Breast Cancer Drug Mechanisms Cellular responses to anticancer drugs Drug Resistance Reversal of drug resistance
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
per: Nicole A. Traphagen (16677391)
Publicat: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
per: Alex C.H. Liu (14961921)
Publicat: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
per: Alex C.H. Liu (14961921)
Publicat: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
per: Alex C.H. Liu (14961921)
Publicat: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
per: Alex C.H. Liu (14961921)
Publicat: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
per: Alex C.H. Liu (14961921)
Publicat: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
per: Alex C.H. Liu (14961921)
Publicat: (2025)

Supplementary Data from Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer
per: Lixuan Wei (14962431)
Publicat: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Supplementary Table 1 from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
per: Juliana Navarro-Yepes (17079059)
Publicat: (2025)

Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
per: Ossia M. Eichhoff (14964145)
Publicat: (2025)

Table ST2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
per: Ossia M. Eichhoff (14964145)
Publicat: (2025)

Table ST3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
per: Ossia M. Eichhoff (14964145)
Publicat: (2025)

Table ST4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
per: Ossia M. Eichhoff (14964145)
Publicat: (2025)

Table ST5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
per: Ossia M. Eichhoff (14964145)
Publicat: (2025)

Table ST6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
per: Ossia M. Eichhoff (14964145)
Publicat: (2025)

Table ST7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
per: Ossia M. Eichhoff (14964145)
Publicat: (2025)

Table ST8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
per: Ossia M. Eichhoff (14964145)
Publicat: (2025)

Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
per: Ossia M. Eichhoff (14964145)
Publicat: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
per: Yufang Bao (15386826)
Publicat: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
per: Yufang Bao (15386826)
Publicat: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
per: Yufang Bao (15386826)
Publicat: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
per: Yufang Bao (15386826)
Publicat: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
per: Yufang Bao (15386826)
Publicat: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
per: Kavya Ramkumar (16474203)
Publicat: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
per: Milana A. Bergamino (15038015)
Publicat: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
per: Milana A. Bergamino (15038015)
Publicat: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
per: Milana A. Bergamino (15038015)
Publicat: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
per: Milana A. Bergamino (15038015)
Publicat: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
per: Milana A. Bergamino (15038015)
Publicat: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
per: Milana A. Bergamino (15038015)
Publicat: (2025)

Supplementary Movie S1 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
per: Fang Wei (15057172)
Publicat: (2025)

Supplementary Movie S2 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
per: Fang Wei (15057172)
Publicat: (2025)

Supplementary Movie S3 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
per: Fang Wei (15057172)
Publicat: (2025)

Cannot write session to /tmp/vufind_sessions/sess_r10k8oagmv5t4hlbh7cj152pgn